WASHINGTON DC—A new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no other options to prevent the progress of this fatal phase of the disease. At the American Association for Cancer Research annual meeting Dr Daniel W. Lee from the Pediatric Oncology Branch of the National Cancer Institute in Bethesda, Maryland, presented findings from his group’s study using chimeric antigen receptor T-cell therapy, which involves removing T cells from the child, stimulating and genetically engineering them before re-infusing them in a primed state to fight the cancer. He discussed the clinical implications with Peter Goodwin.
You may also like...
Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer 16 Oct, 2007 Colorectal cancer screening: survey of 11 European countries finds big mortality benefit 6 Nov, 2013 Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer 15 Feb, 2008 Dog walking cuts breast cancer recurrence risk 29 Mar, 2013
- Previous story Treating HER 2 positive metastatic breast cancer without chemotherapy?
- Next story Gene expression and molecular pathways guide head and neck cancer therapies
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014